PULM Pulmatrix, Inc.
Price Chart
Executive Summary
Pulmatrix filed a Rule 425 communication on behalf of Eos SENOLYTIX, announcing preclinical data for PTC-2105 at the Sachs Obesity Forum. The filing reiterates the pending merger with Pulmatrix (expected Q3 2026) and highlights PTC-2105's potential in body composition and survival. No new financial terms or deal changes were disclosed.
Actionable Insight
This is a routine M&A communication with no new financial or deal-structure information. The preclinical data is promotional and does not change the merger timeline or terms. Monitor for the S-4 proxy statement/prospectus and stockholder vote for the next material catalyst.
Key Facts
- Eos SENOLYTIX presented preclinical data for PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum on June 5, 2026.
- PTC-2105 demonstrated reductions in fat mass greater than GLP-1s, gains in lean mass, and improved physical function in preclinical studies.
- In naturally aged mice, 40% of the PTC-2105 25 mg/kg cohort remained alive at 146 weeks vs. 100% mortality in controls by 137 weeks (p=0.0142).
- The merger between Pulmatrix and Eos was announced March 26, 2026, expected to close in Q3 2026, with combined company trading under ticker MTXL.
- No changes to merger terms, deal value, or timeline were disclosed in this filing.
Financial Impact
No financial figures disclosed; preclinical data only.
Risk Factors
- Preclinical results may not translate to clinical outcomes.
- Merger closing is subject to stockholder approval and customary conditions.
- Combined company needs merger-associated financings to support pipeline advancement.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001493152-26-027416 |
| Document: 0001493152-26-027416-index-headers.html | 0001493152-26-027416 |
| Document: 0001493152-26-027416-index.html | 0001493152-26-027416 |
| Document: 0001493152-26-027416.txt | 0001493152-26-027416 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
7d ago
|
425
| $1.31 awaiting T+1 | awaiting T+1 | — | $1.40 (+7.28%) |
|
Jun 4, 2026
8d ago
|
S-3
| $1.32 $1.33 | ▼ −0.76% | ▼ −3.36% | $1.40 (−6.06%) |
|
May 15, 2026
28d ago
|
8-K
| $1.25 $1.26 | ▲ +0.80% | ▲ +0.86% | $1.40 (+12.00%) |
|
Apr 21, 2026
7w ago
|
8-K
| $1.38 $1.40 | ▲ +1.45% | ▲ +0.43% | $1.40 (+1.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access